Lawrence H. Fong

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Margaret A. Tempero · 3 shared papers, 2020–2023 · strength 0.32
   • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
   • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
   • Paper Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancr… DOI 10.1016/j.ymthe.2020.07.017↗
2. Lisa M. Coussens · 2 shared papers, 2021–2023 · strength 0.23
   • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
   • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
3. Duxin Sun · 1 shared paper, 2026 · strength 0.22
   • Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7↗
4. Christopher I. Li · 1 shared paper, 2026 · strength 0.22
   • Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7↗
5. Vaibhav Sahai · 1 shared paper, 2026 · strength 0.22
   • Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7↗
6. Deepak Nagrath · 1 shared paper, 2026 · strength 0.22
   • Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7↗
7. Meenal Sinha · 1 shared paper, 2023 · strength 0.13
   • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
8. Gina M. Vaccaro · 1 shared paper, 2023 · strength 0.13
   • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
9. Li Zhang · 1 shared paper, 2023 · strength 0.13
   • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
10. Charles D. Lopez · 1 shared paper, 2023 · strength 0.13
    • Paper Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic p… DOI 10.1136/jitc-2022-005425↗
11. Naureen Starling · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
12. Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
13. Josep M. Tabernero · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
14. Rocio García‐Carbonero · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
15. Sara Lonardi · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
16. Joan Maurel Santasusana · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
17. Do‐Youn Oh · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
18. Dirk Waldschmidt · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
19. Michele Reni · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
20. Jean‐Baptiste Bachet · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
21. Eric Van Cutsem · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
22. Teresa Mercade Macarulla · 1 shared paper, 2021 · strength 0.10
    • Paper Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancr… DOI 10.1016/j.annonc.2021.01.070↗
23. Andrew H. Ko · 1 shared paper, 2020 · strength 0.09
    • Paper Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancr… DOI 10.1016/j.ymthe.2020.07.017↗
24. Carl H. June · 1 shared paper, 2020 · strength 0.09
    • Paper Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancr… DOI 10.1016/j.ymthe.2020.07.017↗
25. Alan Paul Venook · 1 shared paper, 2020 · strength 0.09
    • Paper Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancr… DOI 10.1016/j.ymthe.2020.07.017↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.